Yuji Kumagai
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications
Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants.
Journal: Antimicrobial agents and chemotherapy
Published: June 09, 2026
CCL5 enhances invasion of squamous cell carcinoma via syndecan-1-dependent ERK signaling.
Journal: Cell structure and function
Published: May 20, 2026
Effects of Nacubactam and Its Metabolites on QTc Interval: A Pooled Analysis of Two Randomized Phase 1 Studies.
Journal: Clinical and translational science
Published: April 25, 2026
Phase I studies assessing safety and pharmacokinetics of nacubactam administered alone or in combination with cefepime or aztreonam in Japanese healthy participants.
Journal: Antimicrobial agents and chemotherapy
Published: April 13, 2026
Comparison of the characteristics of healthy volunteers participating in Phase 1 clinical trials in Korea and Japan.
Journal: Translational and clinical pharmacology
Published: August 21, 2025
Identification and Characterization of Three Novel Biomarkers for Mixed/Cholestatic Drug-Induced Liver Injury.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: June 09, 2025
Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation.
Journal: The Journal of pharmacology and experimental therapeutics
Published: April 05, 2025
Safety and Efficacy of Ephedrine Alkaloids-Free Ephedra Herb Extract (EFE) for Mild COVID-19: A Double-Blind, Placebo-Controlled, Randomized Comparative Trial.
Journal: Microorganisms
Published: February 28, 2025
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine.
Journal: The Lancet. Infectious diseases
Published: August 30, 2024
Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies.
Journal: British journal of clinical pharmacology
Published: August 28, 2024
Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
Journal: The Lancet. Infectious diseases
Published: June 05, 2024
Using a Quality Management System and Risk-based Approach in Observational Studies to Obtain Robust Real-World Evidence.
Journal: Therapeutic innovation & regulatory science
Published: May 14, 2024
Last Updated: 09/26/2026